MX2021012354A - Formulación para suministro oral de proteínas, péptidos y moléculas pequeñas con poca permeabilidad. - Google Patents

Formulación para suministro oral de proteínas, péptidos y moléculas pequeñas con poca permeabilidad.

Info

Publication number
MX2021012354A
MX2021012354A MX2021012354A MX2021012354A MX2021012354A MX 2021012354 A MX2021012354 A MX 2021012354A MX 2021012354 A MX2021012354 A MX 2021012354A MX 2021012354 A MX2021012354 A MX 2021012354A MX 2021012354 A MX2021012354 A MX 2021012354A
Authority
MX
Mexico
Prior art keywords
formulation
oral delivery
peptides
proteins
total weight
Prior art date
Application number
MX2021012354A
Other languages
English (en)
Inventor
Gene M Dubowchik
Charles M Conway
Vincent Plassat
Benoit Hilbold
Aurélia Galus
Thomas Pointeaux
Julien Meissonnier
Original Assignee
Scherer Technologies Llc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Llc R P filed Critical Scherer Technologies Llc R P
Publication of MX2021012354A publication Critical patent/MX2021012354A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La presente descripción se relaciona con una formulación farmacéutica destinada para suministro oral de inhibidores del péptido relacionado con el gen para calcitonina, escasamente soluble, sintético o natural, o sales/solvatos de las mismas que tengan una actividad terapéutica. La formulación farmacéutica puede incluir inhibidores de CGRP escasamente permeables, sintéticos o naturales, o una sal o solvato de la misma en una cantidad de 0.01 a 10% en peso del peso total de la formulación, una fase lipofílica constituida de triglicéridos de ácidos grasos en una cantidad de 50 a 80% en peso del peso total de la formulación y por lo menos un tensioactivo lipofílico que comprende ésteres parciales de poliol y ácidos grasos en una cantidad de aproximadamente 10 a 50% en peso del peso total de la formulación.
MX2021012354A 2019-04-11 2020-04-10 Formulación para suministro oral de proteínas, péptidos y moléculas pequeñas con poca permeabilidad. MX2021012354A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832508P 2019-04-11 2019-04-11
PCT/US2020/027800 WO2020210722A1 (en) 2019-04-11 2020-04-10 Formulation for oral delivery of proteins, peptides and small molecules with poor permeability

Publications (1)

Publication Number Publication Date
MX2021012354A true MX2021012354A (es) 2021-10-22

Family

ID=70476554

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021012354A MX2021012354A (es) 2019-04-11 2020-04-10 Formulación para suministro oral de proteínas, péptidos y moléculas pequeñas con poca permeabilidad.
MX2021012356A MX2021012356A (es) 2019-04-11 2020-04-10 Formulación para suministro oral de proteínas, péptidos y moléculas pequeñas con poca permeabilidad.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012356A MX2021012356A (es) 2019-04-11 2020-04-10 Formulación para suministro oral de proteínas, péptidos y moléculas pequeñas con poca permeabilidad.

Country Status (17)

Country Link
US (3) US20220249468A1 (es)
EP (2) EP3952899A1 (es)
JP (2) JP2022526196A (es)
KR (2) KR20210151185A (es)
CN (2) CN113784722A (es)
AR (1) AR118654A1 (es)
AU (2) AU2020270985A1 (es)
BR (2) BR112021020287A2 (es)
CA (2) CA3136485A1 (es)
CO (2) CO2021012462A2 (es)
EA (2) EA202192792A1 (es)
IL (2) IL287084A (es)
MX (2) MX2021012354A (es)
SG (2) SG11202110546UA (es)
TW (1) TWI834862B (es)
WO (2) WO2020210722A1 (es)
ZA (1) ZA202108909B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
EP0684834A4 (en) * 1993-02-17 1996-09-25 Smithkline Beecham Corp MICROEMULSIONS CONTAINING THERAPEUTIC PEPTIDES.
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
RU2003128971A (ru) 2001-02-27 2005-03-10 Астразенека Аб (Se) Фармацевтический препарат
EE200400024A (et) * 2001-06-21 2004-06-15 Pfizer Products Inc. Kolesterüülestri ülekandevalgu inhibiitorite iseemulgeeruvad formulatsioonid
ATE424815T1 (de) * 2001-12-03 2009-03-15 Dor Biopharma Inc Stabilisierte umkehr-mizellen-zusammensetzungen und ihre verwendung
MXPA04011960A (es) 2002-06-05 2005-03-31 Squibb Bristol Myers Co Antagonistas de receptores de peptidos relacionados con el gen de calcitonina.
US20050249802A1 (en) 2004-05-06 2005-11-10 The Procter & Gamble Company Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
CN101048137A (zh) * 2004-10-29 2007-10-03 诺瓦提斯公司 可自发分散的药物组合物
CN101065115A (zh) * 2004-11-24 2007-10-31 默克公司 取代酰胺的液体和半固体口服药物制剂
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
CN101511184A (zh) * 2006-09-08 2009-08-19 默克公司 用于口服给药cgrp拮抗剂的液体药物制剂
EP2157967B1 (en) * 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US8323695B2 (en) 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
US20100210561A1 (en) * 2007-09-11 2010-08-19 Dorian Bevec Use of peptide as a therapeutic agent
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
JP6109574B2 (ja) 2009-12-18 2017-04-05 カタラン、フランス、バインハイム、ソシエテ、アノニムＣａｔａｌｅｎｔ Ｆｒａｎｃｅ Ｂｅｉｎｈｅｉｍ Ｓａ 合成オリゴサッカリドを含有する医薬経口剤形
US8481546B2 (en) * 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
MY188825A (en) * 2012-05-18 2022-01-06 Genentech Inc High-concentration monoclonal antibody formulations
CA2898408C (en) 2013-02-28 2018-01-02 Pfizer Inc. Enhanced stability of novel liquid compositions
US8859623B1 (en) 2013-11-14 2014-10-14 Paragon BioTeck, Inc. Methods and compositions of stable phenylephrine formulations
JP2017515852A (ja) * 2014-05-16 2017-06-15 ソーク インスティテュート フォー バイオロジカル スタディーズ 代謝障害を処置するための組成物および方法
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
WO2017093810A2 (en) * 2015-10-14 2017-06-08 Pharcon Inc. Composition for intraoral delivery of biologically active peptides and proteins
CN109589305B (zh) * 2018-12-03 2021-03-19 昆明积大制药股份有限公司 多西他赛-环孢素a共包载自乳化制剂及其制备方法

Also Published As

Publication number Publication date
CN113784722A (zh) 2021-12-10
CN113966223A (zh) 2022-01-21
TWI834862B (zh) 2024-03-11
JP2022526196A (ja) 2022-05-23
AU2020272059A1 (en) 2021-12-09
JP2022526833A (ja) 2022-05-26
KR20210151185A (ko) 2021-12-13
EA202192792A1 (ru) 2022-01-11
EP3952900A1 (en) 2022-02-16
IL287084A (en) 2021-12-01
MX2021012356A (es) 2021-11-04
CA3136485A1 (en) 2020-10-15
US20200323985A1 (en) 2020-10-15
AR118654A1 (es) 2021-10-20
IL287131A (en) 2021-12-01
EA202192793A1 (ru) 2022-01-12
WO2020210722A1 (en) 2020-10-15
CO2021014899A2 (es) 2021-11-19
CO2021012462A2 (es) 2021-09-30
EP3952899A1 (en) 2022-02-16
SG11202110546UA (en) 2021-10-28
US20220143188A1 (en) 2022-05-12
WO2020210723A1 (en) 2020-10-15
BR112021018817A2 (pt) 2021-11-23
TW202103726A (zh) 2021-02-01
US20220249468A1 (en) 2022-08-11
ZA202108909B (en) 2022-07-27
SG11202111251SA (en) 2021-11-29
US11185589B2 (en) 2021-11-30
CA3134550A1 (en) 2020-10-15
AU2020270985A1 (en) 2021-12-09
KR20210151187A (ko) 2021-12-13
BR112021020287A2 (pt) 2021-12-14

Similar Documents

Publication Publication Date Title
HRP20211415T1 (hr) Brzodjelujući pripravci inzulina
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
US8148328B2 (en) Salicylanilides enhance oral delivery of therapeutic peptides
JP2023179467A (ja) 投与および処置の方法
CN103764159A (zh) 芳香族阳离子肽及其用途
Kosugi et al. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi‐scid/scid mice
CL2017002488A1 (es) Formulación farmacéutica estable para administración intratecal que comprende una proteína arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que además puede contener un agente estabilizante; contenedor que comprende dicha formulación; uso para tratar la enfermedad leucodistrofia metacrómatica (mld). (divisional solicitud 3654-2012)
CN104023737A (zh) 抑制被激活受体的肽及其在化妆品组合物或药物组合物中的用途
PE20191716A1 (es) Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
BRPI0814097A8 (pt) Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado
MX2016001971A (es) Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos.
MX2021012354A (es) Formulación para suministro oral de proteínas, péptidos y moléculas pequeñas con poca permeabilidad.
AR062775A1 (es) Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamento
AR114325A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
UY38068A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
WO2018116165A3 (en) Therapeutically active complexes
MX2021009921A (es) Preformulacion de lipidos de liberacion sostenida y composicion farmacetica de liberacion sostenida inyectable en la forma de una solucion de lipidos que contiene a la misma.
NZ702342A (en) Pharmaceutical formulation
KR20200102432A (ko) 신규 조성물
CO2022005904A2 (es) Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CO2022000575A2 (es) Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico
Um et al. Substance P and thiorphan synergically enhance angiogenesis in wound healing
KR20150065736A (ko) 안지오텐신의 경구 제형
Su et al. In vitro and in vivo antiangiogenic activity of a novel deca-peptide derived from human tissue-type plasminogen activator kringle 2